CRIPTO-1 表达在非小细胞肺癌患者中的预后价值：系统评价和荟萃分析。
Prognostic value of cripto-1 expression in non-small-cell lung cancer patients: a systematic review and meta-analysis.
机构信息
Department of Pathology, The First Affiliated Hospital to Shihezi University School of Medicine, Shihezi University School of Medicine, Shihezi 832002, Xinjiang, China.
Key Laboratory of Xinjiang Endemic and Ethnic Diseases (Ministry of Education), Shihezi University School of Medicine, North 2nd Road, Shihezi 832002, Xinjiang, China.
出版信息
Biomark Med. 2020 Mar;14(4):317-329. doi: 10.2217/bmm-2019-0159. Epub 2020 Mar 5.
This systematic review and meta-analysis aimed to analyze the association between cripto-1 expression and prognosis as well as clinicopathological features of non-small-cell lung cancer (NSCLC) patients. The electronic databases for all articles about NSCLC and cripto-1 expression were searched. Twelve articles were enrolled in this meta-analysis (3130 samples). In NSCLC patients, cripto-1 was expressed higher than in normal tissues. Cripto-1 expression was closely correlated with lymph node metastasis, histological differentiation and advanced clinical stage of NSCLC patients, but not related to smoking, age and gender. Pooled hazard ratios found that high cripto-1 expression had poor overall survival and progression-free survival. Cripto-1 could serve as a novel biomarker for predicting poor prognosis in NSCLC patients.
本系统评价和荟萃分析旨在分析 crypt o-1 表达与非小细胞肺癌 (NSCLC) 患者预后及临床病理特征的关系。检索了所有关于 NSCLC 和 crypt o-1 表达的文章的电子数据库。共有 12 篇文章纳入荟萃分析（3130 例样本）。在 NSCLC 患者中，crypt o-1 的表达高于正常组织。Crypt o-1 的表达与 NSCLC 患者的淋巴结转移、组织学分化和临床晚期密切相关，但与吸烟、年龄和性别无关。合并的风险比发现，高 crypt o-1 表达与总生存期和无进展生存期不良相关。Crypt o-1 可作为预测 NSCLC 患者预后不良的新型生物标志物。
Zotero 插件